MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 
Similar Articles
The Motley Fool
March 28, 2008
Brian Lawler
Vertex Tantalizes Us With Very Early Data Vertex announces positive early-stage data for a cystic fibrosis drug. mark for My Articles similar articles
Chemistry World
June 9, 2015
Phillip Broadwith
Vertex nabs rights to cystic fibrosis molecules Specialist pharmaceutical firm Vertex has struck a development deal with start-up Parion Sciences to develop Parion's investigational drug candidates for respiratory diseases, including cystic fibrosis. mark for My Articles similar articles
Fast Company
November 1, 2007
Tinker Ready
Drug Flow and Deal Flow The news at this year's Biotech Investing confab will focus on Big Pharma companies, as they take a more active role in developing early-stage drugs. mark for My Articles similar articles
The Motley Fool
July 21, 2010
Ryan McBride
Eli Lilly Pays up to $380M for Alnara Pharma Indianapolis-based Lilly is paying $180 million upfront for all of Alnara's shares, and shareholders are eligible for as much as $200 million in additional payments depending on whether certain regulatory and commercial milestones are met. mark for My Articles similar articles
Chemistry World
September 7, 2015
Cancer Drugs Fund axes 23 treatments The Cancer Drugs Fund, which covers the cost of some cancer treatments that are not currently available on the National Health Service, has cut 23 treatments -- involving 16 drugs. mark for My Articles similar articles
The Motley Fool
July 27, 2004
Charly Travers
Cash Concerns at Vertex New royalties might not help offset losses at the pharmaceutical, so it's time to look at the drug pipeline. mark for My Articles similar articles
Pharmaceutical Executive
April 1, 2011
Winning Beyond the Molecule It can take both a clinical and non-clinical approach to win the differentiation competition. mark for My Articles similar articles
The Motley Fool
June 29, 2009
Brian Orelli
Funding From an Unlikely Place Nonprofits still have money, and they seem willing to fork it over to for-profit drug companies. mark for My Articles similar articles
The Motley Fool
July 22, 2011
Brian Orelli
That's All the Melanoma Market Is Worth? BioSante licenses out its melanoma vaccine for $100,000. mark for My Articles similar articles
The Motley Fool
June 9, 2011
Brian Orelli
It's a Numbers Game With Vertex In the longer term, the number of patients Vertex can address with its cystic fibrosis drugs will play a major role in its valuation. mark for My Articles similar articles
The Motley Fool
April 23, 2008
Brian Lawler
Vertex Verging on Crucial News Soon-to-arrive study results could decide the future of Vertex Pharmaceutical's lead drug telaprevir. mark for My Articles similar articles
The Motley Fool
August 4, 2010
Ryan McBride
How Eli Lilly Let a Billion-Dollar Molecule Slip Away, and Make a Fortune for Vertex The remains of Lilly's partnership with Vertex Pharmaceuticals. mark for My Articles similar articles
The Motley Fool
October 28, 2011
Brian Orelli
Invest in Biotechs Going After Unmet Needs What a quarter it was for Vertex Pharmaceuticals: $420 million in net sales of its new hepatitis C drug. mark for My Articles similar articles
AFP eWire
April 9, 2007
Foundation Giving Rises to $40 Million Foundation giving in the United States grew to $40.7 billion in 2006, an 11.7% increase from the previous year, according to a new study. mark for My Articles similar articles
The Motley Fool
March 27, 2007
Fast Pitch: Vertex Pharmaceuticals 2007 is expected to be a very eventful year for the pharmaceutical, as it will furnish some important clinical trial results for its investigational drugs. Investors, take note. mark for My Articles similar articles
AFP eWire
April 12, 2004
U.S. Foundation Giving Declines Slightly in 2003 Grantmaking foundations in the United States gave slightly less in 2003 campared to the previous year. mark for My Articles similar articles
U.S. Banker
June 2002
John Hackett
Can't Go Wrong As more Americans set up private foundations, banks find that not only do they bring in money directly, they also attract other wealth management business. mark for My Articles similar articles
The Motley Fool
March 20, 2009
Brian Orelli
EU to Gilead: More Trials for You The U.S. isn't ready for Gilead Sciences' new cystic fibrosis drug, and neither is Europe. mark for My Articles similar articles
Managed Care
June 2003
Effectiveness of review process in eye of beholder From January 1999 to December 2000, 263 independent medical reviews were conducted in California as a result of patients trying to overturn coverage decisions by health plans. The Institute of Medical Quality surveyed those patients to obtain their opinions on the review process. mark for My Articles similar articles
AFP eWire
April 24, 2006
Slow, Steady Foundation Growth Seen in 2005, Expected in 2006 A new report shows steady, but unremarkable growth for the foundation sector in 2005 and forecasts much of the same for 2006. mark for My Articles similar articles
The Motley Fool
September 8, 2010
Brian Orelli
You Must Realize This Drug Works by Now Vertex concludes its phase 3 trials with another win. mark for My Articles similar articles
The Motley Fool
March 30, 2009
Brian Orelli
Change the Game? Change the Rules! There are ways for investors to get around Obama's plan to lower health care costs. Investing in drug companies in this time of "change" doesn't have to be scary. You've just got to find rule breaker-type drugmakers, because playing by the rules isn't going to cut it anymore. mark for My Articles similar articles
The Motley Fool
September 9, 2004
Charly Travers
The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated. mark for My Articles similar articles
Inc.
December 2006
Daniel Akst
Foundations R Us You can give it away as smartly as you made it. mark for My Articles similar articles
The Motley Fool
June 9, 2011
Brian D. Pacampara
Vertex Pharmaceuticals Shares Plunged: What You Need to Know Shares of drug developer Vertex Pharmaceuticals sank as much as 13% after reporting initial data on their combination cystic fibrosis treatment. mark for My Articles similar articles
The Motley Fool
March 31, 2011
Brian Orelli
Hepatitis C Drugs Heat Up The current hepatitis C drugs stink. Who's ahead in the race to find new ones? mark for My Articles similar articles
Chemistry World
July 31, 2012
Andrew Turley
New cystic fibrosis drug in EU Ivacaftor, which is marketed under the brand name Kalydeco, won US approval in January. mark for My Articles similar articles
The Motley Fool
October 31, 2011
Brian Orelli
5 One-Drug Wonders Going for No. 2 Here are five drugmakers hoping not to become one-hit wonders: Vertex... Onyx... Momenta... Elan... Dendreon... mark for My Articles similar articles
The Motley Fool
August 4, 2008
Brian Lawler
Vertex on the Verge of Victory Like the majority of biotech drugmakers, Vertex's financials proved less crucial in the second quarter than the clinical trial results from the drugmaker's pipeline. mark for My Articles similar articles
Managed Care
February 2004
Bob Carlson
Finding Common Ground: Where Foundations, MC Meet Tapping into local foundations' expertise and knowledge is one way managed care can start to reinvent itself. mark for My Articles similar articles
AFP eWire
May 17, 2004
Report Reveals What Grantees Value in Foundations A new report from the Center for Effective Philanthropy has identified several key areas that charity grantees most value in the foundations that fund their programs. mark for My Articles similar articles
AFP eWire
May 19, 2008
Advice to Grant Seekers: Never Believe Your Own PR Grant seekers should remember to bring their data and a level head -- not a sales pitch -- when they approach a foundation for grant money. mark for My Articles similar articles
HBS Working Knowledge
June 28, 2010
Julia Hanna
HBS Cases: Cincinnati Children's Hospital Medical Center This case explores how one hospital implemented its own version of health-care reform, taking overall performance levels from below average to the top 10 percent in the industry. mark for My Articles similar articles
Foundation News & Commentary
Sep/Oct 2006
Francie Ostrower
Staying the Course A new study of community foundation effectiveness generates suggestions for increasing grantmaking impact. mark for My Articles similar articles
The Motley Fool
June 22, 2004
Charly Travers
Merck Pays Up for a Cancer Drug As demonstrated this morning with the announcement of a major deal with Vertex Pharmaceuticals, Merck is now in the midst of a strategic push to build out its oncology pipeline. mark for My Articles similar articles
Foundation News & Commentary
Nov/Dec 2005
Simone & Venkat
Planning for Consistency Corporate grantmakers can achieve stability through creating endowments, quasi-endowments and reserves. Here's how. mark for My Articles similar articles
PC Magazine
March 16, 2005
Cade Metz
Your Request Is Granted We go inside the soup-to-nuts Web site for running charitable foundations online. mark for My Articles similar articles
The Motley Fool
November 3, 2008
Dan Caplinger
Do Good Without Being a Corporate Hotshot Don't let modest means stop you from giving what you can to charity. mark for My Articles similar articles
The Motley Fool
July 29, 2011
Brian Orelli
Vroom! There Goes Vertex Vertex Pharmaceuticals' Incivek launch is off to a good start. mark for My Articles similar articles
The Motley Fool
March 4, 2009
Brian Orelli
Vertex Combines to Keep From Being Ground Up Vertex Pharmaceuticals announces that it is buying ViroChem Pharma, getting two early stage hepatitis C compounds in the deal. mark for My Articles similar articles
The Motley Fool
April 21, 2011
Brian Orelli
Who's Next? 5 Potential Biotech Takeover Targets Exelixis has reportedly hired Goldman Sachs to shop the development-stage drugmaker around to the highest bidder. With an asset like XL184, there should be someone interested. mark for My Articles similar articles
Foundation News & Commentary
Mar/Apr 2006
Communications Par Excellence Here are the Council on Foundations' Wilmer Shields Rich Awards for Excellence in Communications program, which recognizes and encourages effective communications by foundations and corporate giving programs: Skoll Foundation... etc. mark for My Articles similar articles
The Motley Fool
October 19, 2007
Brian Lawler
Schering's Gain Is Only a Mild Headache for Vertex Schering-Plough's strong phase 2 clinical results of its hepatitis C virus drug candidate send shares of competitor Vertex down. mark for My Articles similar articles
The Motley Fool
January 24, 2008
Brian Lawler
Vertex Under the Gun Vertex announces development plans for its lead drug. Investors, take note. mark for My Articles similar articles
Foundation News & Commentary
Sep/Oct 2005
Freeland & Royal
Perpetuating Community Philanthropy Here's how one foundation rose to the challenge of being more entrepreneurial and innovative to stimulate economic growth throughout the community. mark for My Articles similar articles
Foundation News & Commentary
Mar/Apr 2005
Celebrating Strategic Communications Here are the winners of the Council on Foundations' Wilmer Shields Rich Awards for Excellence in Communications. The awards recognize and encourage effective communications by foundations and corporate giving programs. mark for My Articles similar articles
Financial Planning
October 1, 2008
Jim Grote
Foundations for Renown Assets in domestic private foundations are growing and donors are demanding more customized service from advisory firms. mark for My Articles similar articles
The Motley Fool
December 16, 2011
Brian Orelli
Biotech Royalties, Almost as Good as Cash They're flexible, and all royalties have value. mark for My Articles similar articles
Inc.
May 1, 2002
Donna Fenn
Shaking the Foundations Sanjay Chopra is an astute donor. The founder of two technology companies recently joined 59 other fledgling philanthropists to give $50,000 to KidsVoice, a Pittsburgh nonprofit that provides legal services to children in juvenile court... mark for My Articles similar articles
The Motley Fool
November 30, 2010
Dan Caplinger
You Don't Have to Be Rich to Do Good Supporting charity isn't just for billionaires. mark for My Articles similar articles